



Please add the following new claims 15 to 22.


15. A compound ~~according to claim 1~~ of the formula



wherein  $R_1$  is a group of the formula




IIa,



IIb


or



IIId

and  $R_2$  is hydrogen

or  $R_1$  and  $R_2$  together is a group of formula



IIh

wherein  $R_7$  is hydrogen or lower alkoxy,

$R_8$  and  $R_9$  are each hydrogen,

$X$  is oxygen or sulphur,

$p$  is 1,


$s$  is 4,

$R_3$  and  $R_5$  are hydrogen

$R_4$  is  $C_{1-6}$  alkyl or


$R_3$  and  $R_4$  together are  $-(CH_2)_4-$  and  $R_1$  is a group of formula IIa, IIb or IIId, and

$R_6$  is a group of the formula



IIIa

or



IIIc


where  $R_{11}$  is hydrogen, alkyl, alkenyl, cycloalkyl, phenyl or thienyl,

$R_{12}$  is hydrogen or lower alkyl and


Z is  $-(CH_2)_5^-$  or

a chemotherapeutically acceptable acid addition salt thereof


16. A compound according to claim 15 of the formula



wherein  $R_1$  is a group of the formula




IIa,



IIb

or



IIc

wherein  $R_7$  is hydrogen or lower alkoxy

$R_8$  and  $R_9$  are each hydrogen,

X is oxygen or sulphur,


s is 4;

$R_2$ ,  $R_3$  and  $R_5$  are each hydrogen

$R_4$  is  $C_{1-6}$  alkyl or


$R_3$  and  $R_4$  together are  $-(CH_2)_4^-$ , and

$R_6$  is a group of the formula



IIIa

or



IIIc


where  $R_{11}$  is hydrogen, alkyl, alkenyl, cycloalkyl, phenyl or thienyl,

$R_{12}$  is hydrogen or lower alkyl and

Z is  $-(CH_2)_5$  or

a chemotherapeutically acceptable acid addition salt thereof.

17. A compound according to claim 15 of the formula:



wherein  $R_1$  is a radical of formula IIa,



$R_2$ ,  $R_3$ ,  $R_5$ ,  $R_7$  and  $R_8$  are each hydrogen,

$R_4$  is alkyl of 1 to 4 carbon atoms, and

$R_6$  is a radical of formula IIIa



where  $R_{11}$  is alkyl of 3 to 5 carbon atoms or a chemotherapeutically acceptable acid addition salt thereof.--

18. A compound of Claim 15 wherein  $R_6$  represents a group of formula IIIa wherein  $R_{11}$  represents alkyl preferably  $C_2$ - $C_8$ alkyl, more preferably  $C_2$ - $C_6$ alkyl most preferably  $C_2$ - $C_4$ alkyl for example n- or in particular t-butyl.

19. A compound according to claim 15 selected from the group consisting of

- a) trans-N-(3-benzo[b]thiophenemethyl)-N-methyl-non-2-en-4-ynyl-1-amine;
- b) cis-N-(3-benzo[b]thiophenemethyl)-N-methyl-non-2-en-4-ynyl-1-amine;
- c) trans-N-methyl-N-(1-naphthylmethyl)-6-hydroxy-6-methyl-hex-2-en-4-ynyl-1-amine;
- d) N-methyl-N-(1-naphthylmethyl)-deca-2-(trans),6(cis)-dien-4-ynyl-1-amine;
- e) N-methyl-N-(1-naphthylmethyl)-4-cyclohexyl-2-(trans)-4-pentadienyl-1-amine;
- f) N-methyl-N-(1-naphthylmethyl)-4-cyclohexylidenyl-2-(trans)-pentenyl-1-amine; and
- g) trans-N-methyl-N-(1-naphthylmethyl)-4-cyclohexylidenyl-2-buten-yl-amine;

or a chemotherapeutically acceptable acid addition salt thereof.


20. A compound according to claim 15 selected from the group in which  $R_1$  is 1-naphthyl,  $R_2$  is H,  $R_3$  is H,  $R_4$  is  $CH_3$  and  $R_5$ ,  $R_6$  and the configuration are



- a) H,  $-C\equiv C-(CH_2)_3-CH_3$ , and cis;
- b) H,  $-C\equiv CH$ , and trans;
- c) H,  $-C\equiv C-C(CH_3)_3$ , and cis;
- d) H,  $-C\equiv C-\underset{\substack{| \\ C_2H_5}}{\overset{\substack{| \\ CH_3}}{CH}}$ , and trans;
- e) H,  $-C\equiv C-\underset{\substack{| \\ C_2H_5}}{\overset{\substack{| \\ CH_3}}{CH}}$ , and cis;
- f) H,  $-C\equiv C-CH_2-\underset{\substack{| \\ CH_3}}{\overset{\substack{| \\ CH_3}}{CH}}$ , and trans;
- g) H,  $-C\equiv C-CH_2-\underset{\substack{| \\ CH_3}}{\overset{\substack{| \\ CH_3}}{CH}}$ , and cis;

- h) H,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_3-\text{CH}_3$ , and trans;  
 i) H,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_2-\text{CH}_3$ , and trans;  
 j) H,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_4-\text{CH}_3$ , and trans;  
 k) H,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_5-\text{CH}_3$ , and trans;  
 l) H,  $-\text{C}\equiv\text{C}-\text{CH}=\text{CH}-(\text{CH}_2)_2-\text{CH}_3$ , and trans;  
 m) H,  $-\text{C}\equiv\text{C}-\underset{\text{C}_2\text{H}_5}{\text{C}}=\text{CH}-\text{CH}_3$ , and trans;  
 n) H,  $-\text{C}\equiv\text{C}-\underset{\text{CH}_3}{\text{C}}=\text{CH}-\text{CH}_3$ , and trans;  
 o) H,  $-\text{C}\equiv\text{C}-\underset{\text{C}(\text{CH}_3)_3}{\text{C}}=\text{CH}_2$ , and trans;  
 p)  $\text{CH}_3$ ,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_3-\text{CH}_3$ , and trans;  
 q)  $\text{CH}_3$ ,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_3-\text{CH}_3$ , and cis;  
 r) H,  $-\text{C}\equiv\text{C}-\underset{\text{CH}_3}{\overset{\text{CH}_3}{\text{C}}}-\text{C}_2\text{H}_5$ , and trans and  
 s) H,  $-\text{C}\equiv\text{C}-\underset{\text{CH}_3}{\overset{\text{CH}_3}{\text{C}}}-\text{C}_2\text{H}_5$ , and cis,







or a chemotherapeutically acceptable acid addition salt thereof.

21. A compound according to claim 15 selected from the group in which  $\text{R}_2$  is H,  $\text{R}_3$  is H,  $\text{R}_4$  is  $\text{CH}_3$ ,  $\text{R}_5$  is H and  $\text{R}_1$  and  $\text{R}_6$  and the configuration are:

- a) ~~1-naphthyl,  $-\text{C}\equiv\text{C}-\text{C}_6\text{H}_5$  and trans;~~  
 b) 1-naphthyl,  $-\text{C}\equiv\text{C}-\text{C}_6\text{H}_5$  and cis;  
 c) 1-naphthyl,  $-\text{C}\equiv\text{C}-$  , and trans;

- d) 1-naphthyl,  $-\text{C}\equiv\text{C}-$  , and trans;
- e) 1-naphthyl,  $-\text{C}\equiv\text{C}-$  , and cis;
- f) 4-methoxy-1-naphthyl,  $-\text{C}\equiv\text{C}-\text{C}(\text{CH}_3)_3$   
or a chemotherapeutically acceptable acid addition salt thereof.

22. A compound according to claim 15 selected from the group in which  $\text{R}_2$  is H,  $\text{R}_3$  is H,  $\text{R}_4$  is methyl,  $\text{R}_5$  is H and  $\text{R}_1$ ,  $\text{R}_6$  and the configuration are

- B<sup>2</sup>
- a) ,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_3-\text{CH}_3$  and trans;
- b) ,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_3-\text{CH}_3$ , and cis;
- c) ,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_3-\text{CH}_3$ , and trans;
- d) ,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_3-\text{CH}_3$ , and cis;
- e) ,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_3-\text{CH}_3$ , and trans; and
- f) ,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_3-\text{CH}_3$ , and cis; or

from the group in which  $\text{R}_1$  and  $\text{R}_2$  together is

